Home / Treatments / Euflexxa Injection
Euflexxa Injection denials: what the review data shows
Independent reviewers have decided 225 published cases where an insurer denied Euflexxa Injection — and they overturned the insurer 92.9% of the time. A denial for Euflexxa Injection is a starting position, not a final answer.
Published decisions
225
2001–2026
Overturned
92.9%
209 denials reversed
By condition
Published outcomes when Euflexxa Injection was denied for these conditions.
| Condition | Decisions | Overturned |
|---|---|---|
| Osteoarthritis Of The Knee | 125 | 97.6% |
| Knee Osteoarthritis | 27 | 81.5% |
| Osteoarthritis Of The Right Knee | 16 | 100% |
| Osteoarthritis Of The Left Knee | 12 | 100% |
| Osteoarthritis | 12 | 100% |
What the insurer actually argued
Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 218 | 95% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 7 | 28.6% |
Typical time to a decision
8 days
Most land between 3 and 18 days
Handled as urgent
52.4%
Expedited when a delay would cause harm
What the reviewers wrote
Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.
Where the denial was overturned
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for bilateral Euflexxa injections for treatment of the enrollee’s chronic bilateral knee pain. Findings: The physician reviewer found that Evidence based medical peer reviewed literature supports the use of repeat viscosupplementation injections for the treatment of pain in patients with osteoarthritis of the knee. Bannuru and colleagues concluded that hyaluronic acid was the best pharmacologic intervention for knee osteoarthritis in their meta-analysis of 137 studies with 33,243 participants. Hyaluronic acid was found to be better than injected placebo or injected corticosteroids.
Findings: The physician reviewer found that the enrollee has been diagnosed with right knee primary osteoarthritis. The enrollee reported right anterior knee pain and grinding, which limited her activities. Her prior treatment included activity modification and over-the-counter medications. Previous viscosupplementation resulted in long-term pain relief and an improved activity level. The patient underwent a platelet-rich plasma (PRP) injection and reported no substantial benefit. Her current medications included Cymbalta and Mobic. Right knee examination demonstrated patellofemoral tenderness to palpation, especially at the lateral facet. Normal strength and no instability were noted. Radiographs demonstrated mild to moderate lateral patellofemoral compartment joint space narrowing consistent with early to moderate patellofemoral osteoarthritis.
Where the denial was upheld
Worth reading too — these show what an appeal has to overcome.
Nature of Statutory Criteria/ Case Summary: The enrollee requested authorization and coverage for Euflexxa injections. Findings: The physician reviewer found that the enrollee has a history of bilateral knee pain and instability of the patella as well as subluxations and pain rated between 0/10 and 8/10. Patella grind and patella apprehension are both positive. Imaging is negative on x-rays for joint space narrowing. An MRI showed an anterior cruciate ligament (ACL) tear on the right knee, mild chondromalacia and patella alta. An MRI of the left knee showed a degenerative meniscus tear and mild cartilage loss. Treatments for her patella instability include activity modification, and steroid injections. She reports this has helped her, as has her physical therapy treatments.
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for Euflexxa injections for treatment of the enrollee’s knee pain. Findings: The physician reviewer found that The physician reviewer found the submitted documentation fails to demonstrate the medical necessity of the requested services. The medical evidence supports hyaluronic acid injections in the knee as a possible option for patients with severe osteoarthritis who have not responded adequately to recommended conservative treatments for at least three months, including failure to adequately respond to aspiration and injection of intra-articular steroids.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California outcomes — every state runs an equivalent external review, but the rates here are California’s. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
How to use this in your appeal
These are outcomes from California’s external review program — an independent physician panel that binds the insurer. Every state has an equivalent process, and internal appeals succeed even more often. Cite the outcome record for Euflexxa Injectionwhen you appeal: reviewers routinely find that denials like yours didn’t hold up.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.